Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis

Abstract

Increased activity of intestinal alkaline phosphatase (AP) occurs locally in patients with ulcerative colitis (UC), aimed at repairing inflammatory tissue damage. We evaluated the safety and preliminary efficacy of exogenous AP administered to patients with UC in an open-label, first-in-patient exploratory trial, conducted in the Internal Medicine and Gastroenterology hospital departments in the Czech Republic and Italy.

Keywords

• alkaline phosphatase
• ulcerative colitis
• clinical trial
• inflammatory bowel disease